Case study

Measuring the Patient Health Impact of AL Amyloidosis: Capturing Heterogeneous Patient Experiences with the SF-36v2® Health Survey (SF-36v2)

In 2014, the patient experience with immunoglobulin light chain (AL) amyloidosis was not well documented in literature, and there were no existing PRO measures validated for use in studies of patients who have AL amyloidosis. In a free case study, discover how QualityMetric’s SF-36v2 health survey helped a pharmaceutical company identify critical measurement concepts for this rare disease and capture the wide variety of patient experiences, as well as their impact on other domains of patient lives.

Download the Case Study Now

  • Hidden
  • I acknowledge by submitting my information I will be contacted by QM regarding this survey information request and product information.
< Back

Survey License Application

Please answer the following questions and we will be in touch regarding your license

Thank you for your request.

QualityMetric is reviewing your application and will get back to you shortly with approval to move forward with a license to administer, collect, score, and interpret the data for your project/study.

Next steps:

If you have started administering the survey, please email a copy of the survey being administered to [email protected]. We will QA the form for any changes that may affect the scoring and interpretation of the data collected. (Fees may apply).

If you are applying for a student license, please email a copy of your student ID to [email protected].


  • Background info and data on AL amyloidosis in the U.S. population
  • How PRO instruments can capture patient experiences and their impacts
  • The results of recent studies on patients living with AL amyloidosis

A novel approach to determining the patient health impact of AL amyloidosis, the SF-36v2 health survey measures a range of symptoms, experiences and patient health outcomes. This case study discusses how QualityMetric conducted in-depth interviews with clinicians, other experts and patients, as well as an online observational study, providing much-needed granularity into the consequences that AL amyloidosis has on patient lives.